{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+pill&page=15",
    "query": {
      "intervention": "Combination pill",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 341,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+pill&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+pill&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T17:36:58.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02915523",
      "title": "Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        },
        {
          "name": "avelumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2016-12-19",
      "completion_date": "2021-04-21",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 12,
      "location_summary": "Tampa, Florida • West Palm Beach, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915523"
    },
    {
      "nct_id": "NCT00086359",
      "title": "Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Abacavir sulfate, lamivudine, and zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine/zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "13 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2004-07",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086359"
    },
    {
      "nct_id": "NCT03512418",
      "title": "Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "PrEPsteps",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Digital pill",
          "type": "DEVICE"
        },
        {
          "name": "Truvada",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2019-06-20",
      "completion_date": "2024-04-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 1,
      "location_summary": "Boylston, Massachusetts",
      "locations": [
        {
          "city": "Boylston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512418"
    },
    {
      "nct_id": "NCT00860847",
      "title": "Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Atherosclerosis",
        "Coronary Artery Calcification",
        "Coronary Stenosis"
      ],
      "interventions": [
        {
          "name": "Aged garlic extract and Coenzyme Q10",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "84 Years",
        "sex": "MALE",
        "summary": "35 Years to 84 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2009-05",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2015-03-12",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00860847"
    },
    {
      "nct_id": "NCT06334315",
      "title": "Oral Contraceptive Pill (OCP) Pharmacogenomics",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contraception",
        "Pharmacogenomic Drug Interaction"
      ],
      "interventions": [
        {
          "name": "Desogestrel / Ethinyl Estradiol Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 700,
      "start_date": "2024-10-29",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06334315"
    },
    {
      "nct_id": "NCT02513485",
      "title": "Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Levodopa+carbidopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 57,
      "start_date": "2015-10-09",
      "completion_date": "2020-08-01",
      "has_results": true,
      "last_update_posted_date": "2022-09-19",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02513485"
    },
    {
      "nct_id": "NCT00451204",
      "title": "A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Estriol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Copaxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 158,
      "start_date": "2007-03",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-06-16",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00451204"
    },
    {
      "nct_id": "NCT00660725",
      "title": "Study of GemOx and Vandetanib in Advanced Solid Malignancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Incurable Solid Malignancy"
      ],
      "interventions": [
        {
          "name": "Vandetanib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leonard Appleman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2009-02",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-23",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00660725"
    },
    {
      "nct_id": "NCT00112047",
      "title": "Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Emtricitabine (FTC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir Disoproxil Fumarate (TDF)",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz (EFV)",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF/EFV",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine/zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2003-07",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2010-10-13",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00112047"
    },
    {
      "nct_id": "NCT05713799",
      "title": "Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin Resistance",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Alpha-lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-11-11",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-06T17:36:58.806Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05713799"
    }
  ]
}